

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Results from the Phase III KEYNOTE-590 trial demonstrated a survival benefit with first-line pembrolizumab with chemotherapy compared to chemotherapy alone for which of the following patients with advanced esophageal cancers?**
 - a. Patients with adenocarcinoma histology only
 - b. Patients with squamous cell histology only
 - c. Patients with either adenocarcinoma or squamous cell histology**
- 2. Which of the following receptor proteins is the target of the novel antibody bemarituzumab, being investigated for the treatment of gastroesophageal cancers?**
 - a. PD-1
 - b. HER2
 - c. FGFR2b**
- 3. Results of the Phase III CheckMate 577 trial evaluating nivolumab versus placebo as adjuvant therapy for patients with high-risk resected esophageal or gastroesophageal junction cancers demonstrated a significant benefit in disease-free survival with nivolumab in which patient population?**
 - a. Overall intent-to-treat population**
 - b. Patients with tumor cell PD-L1 expression $\geq 1\%$ only
 - c. Patients with tumor cell PD-L1 expression $< 1\%$ only
- 4. Which of the following statements accurately summarizes the results from the Phase II DESTINY-Gastric 01 trial assessing trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with HER2-positive advanced gastric cancer?**
 - a. Better clinical activity with T-DXd**
 - b. Better clinical activity with chemotherapy
 - c. Similar clinical activity with T-DXd and chemotherapy